Shares of Corvus Pharmaceuticals Inc. (CRVS) have gained 100% over the past four months as the clinical-stage biopharmaceutical company anticipates a data release later this month.
The company's lead drug candidate is Soquelitinib (formerly known as CPI-818), an oral small molecule drug designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase). ITK is an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.